Janssen’s teclistamab delivered a major Phase I/IIa win in refractory multiple myeloma, with MajesTEC-9 meeting its primary endpoint and improving progression-free and overall survival. Reporting highlighted a chemotherapy-free approach using a T-cell engager that binds BCMA on myeloma cells and CD3 on T cells, with deeper responses and high rates of minimal residual disease (MRD) negativity referenced as key outcome signals. Regulatory and pipeline context also matters: an accompanying analysis of multiple myeloma clinical trial pipelines found that cell-based therapies represent the largest share of studies over the last decade, with CAR-T and T-cell engagers dominating candidate momentum. The combined items position multiple myeloma as a proving ground for immune-cell therapies—where response depth (including MRD) increasingly functions as a practical barometer for longer-term disease control.